Our Team

Valérie joined Sanofi Ventures in 2020. She previously worked for 30 years in positions of increased responsibility across a number of departments within the Sanofi Group including R&D, Legal and Strategy & Business Development.

Valérie holds a Baccalaureate in Economic & Social Sciences and a B.T.S. in Bilingual Management Assistant. She loves travelling, sports, visiting museums and pop music.

Laia joined Sanofi Ventures in 2018 with a background in early-stage biotech investing and drug development. Prior to Sanofi, Laia served as Investment Director for Ysios Capital where she led investments and served on the board of multiple early-stage companies.

Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia's active investments include OMass Therapeutics, Muna Therapeutics, Therini Bio and NodThera. Previous investments and board roles include Lava Therapeutics (LVTX).

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a Ph.D. with honors. Laia holds an M.B.A. from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.

Cris joined Sanofi Ventures in 2020 to lead investments in digital health and data science innovation. He holds a 20-year track record of building startups and tech innovation platforms with some of the largest organizations in the world. Prior to Sanofi, Cris was a founding member of Johnson & Johnson Innovation and Global Head of Digital Innovation since 2013. He held chief& digital and data responsibilities, driving strategy and external tech collaborations throughout J&J Innovation spanning the Pharmaceutical, Consumer and Medical Device businesses.​

Previously, Cris led emerging technology programs within research informatics at Novartis for six years. With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra Light Startups, one of the largest startup venture pitch accelerators in the U.S, catalyzing hundreds of companies in Boston, NYC, and Silicon Valley, leading to several large-scale acquisitions by major tech companies. Cris was named 40 Under 40 by the Boston Business Journal and a Top 40 Healthcare Transformer by MM&M Magazine.​

Cris currently serves on the boards of Aetion, Click Tx, Empatica, Medisafe, Nucleai, and Omada. Cris holds a M.Sc. in Computer Information Systems from Boston University and a B.S. in Business Administration from Suffolk University.​

Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.

Chris currently serves on the Board of Directors for i2O Therapeutics and Minervax.

Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University.

Jason joined Sanofi Ventures in 2014 with a background in early-stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at Translate Bio (fka RaNA Therapeutics), a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason’s active investments include Abcuro, Amathus Therapeutics, Escient Pharmaceuticals, Expansion Therapeutics, Glycomine, Q32 Bio, ReCode Therapeutics, Rome Therapeutics and Navitor Pharmaceuticals. Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ: KYMR), Ovid Therapeutics (NASDAQ: OVID) Science 37 (NASDAQ: SNCE) and Lysosomal Therapeutics Inc. Jason also serves as the Vice Chair of the Board of Trustees of the Buckingham Browne and Nichols school and the Board of Directors of The Magdalene College Foundation.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Paulina joined Sanofi Ventures in 2022 with a background in early stage biotech investing and company building. Paulina currently serves on the boards of Normunity and Vrata.

Prior to joining Sanofi, Paulina was a Principal on the investment team at Omega Funds where she served as the board director or observer for Scorpion Therapeutics, Arrakis Therapeutics, IFM, and additionally led or co-led Omega’s investments in Theseus (NASDAQ: THRX), Ikena (NASDAQ: IKNA), Synthekine and Vanqua Bio.

Previous to Omega Funds, Paulina began her career with Polaris Partners. Paulina served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Lyra Therapeutics (NASDAQ: LYRA), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at the Massachusetts Institute of Technology. During her time at MIT, Paulina founded the MIT Postdoctoral Association and served as its President. Paulina also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team.

Meg joined Sanofi Ventures in 2021 with a background in biotech investing and business development. She previously worked as Director of Business Development at Vertex Pharmaceuticals, where she was part of the External Innovation team. Prior to Vertex, Meg worked at RA Capital, a crossover investment fund, where her areas of focus included rare diseases, genetic therapies, and neuroscience.

Meg currently serves on the Board of Directors for Veralox.

Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and a B.S. with Honors in Neuroscience from The Pennsylvania State University. She currently sits on the Steering Committee of the New England Venture Network.

Camille joined Sanofi Ventures in 2021. She previously worked for three years in Sanofi’s Business Development team as Director in Transactions, where she led several deals to execution, including digital partnerships with Abbott Diabetes Care and Biocorp.

Camille began her career as a consultant at L.E.K. Consulting, where she focused on strategic due diligences for private equity funds and corporates. She then joined Sanofi as an internal consultant where she provided organizational and strategic support to senior leaders of the group.

Camille holds a Master’s degree in Finance and Corporate Strategy and a Bachelor’s Degree in Social Sciences from Sciences Po in Paris.

Over the last decade, Alba has worked with some of the world's largest organizations in their digital transformation, enabling them to create new growth engines, by investing into, and partnering with the startup ecosystem. 

Prior to Sanofi, Alba was the Global Head of Innovation Strategy for Venture Capital firm 500 Global, one of the most active early-stage investors in the world, where she was responsible for the firm's end-to-end enterprise deal making. Previously, Alba was a senior management consultant with Deloitte Venture Support, serving as an advisor to Japan’s largest enterprises, helping them source, diligence, invest in, and partner with startups.

Alba holds a Ph.D. in Innovation and Technology Management by the University of Tokyo and an M.Sc. in Biotechnology from the Polytechnical University of Valencia.